7/09/2014 @ 9:43AM 2,026 views
'Smart Biotech Hedge Fund Worth Watching Had Therapeutics MD Before Pop'
Bryan Rich Bryan Rich , Contributor
Biotech stock Therapeutics MD (TXMD) was up 32.5% on Tuesday, lifted by brokerage house FBR Capital initiating coverage with an incredible $34 price target. Based on TXMD’s Tuesday closing price of $5.47, the FBR price target would mean a 600% return.
TXMD is owned by the billion-dollar biotech hedge fund RA Capital Management. RA is experienced in the business of biotech investing, and owns more than 6% of TXMD.
RA is one of our favorite hedge funds to piggyback. It’s run by Peter Kolchinsky, a PhD from Harvard. The fund has one of the best track records in the world, averaging 41% a year since 2002.
if this was the real deal you would see this over 6 today. this is a scam and the scam is over. They dumped all their shares and got out this morning. where is the SEC or are they trading it too. This is going right back to 4 where it belongs.